Survival analysis of osteosarcoma patients: A 15-year experience

Abstract

Introduction: Management of osteosarcoma has evolved considerably for the past two decades and there have been changes of practices especially pertaining to chemotherapy regime. This is a review of our cases in the past 15 years. Method: This is a retrospective survival analysis study of 128 patients treated at University Malaya Medical Centre (UMMC) from 1997 to 2011. Results: There were 80 (62.5%) male and 48 (37.5%) female patients with the median age being 15 (5–59). Majority had osteosarcoma of extremities (94.5%). More than 60% patients developed metastasis throughout the course of treatment with 39% presenting with lung metastasis. Osteoblastic osteosarcoma was the commonest subtype (65.6%). Of the 109 patients treated surgically, 84 patients (65.6%) underwent limb salvage surgery while the rest underwent amputation. Seventy-one per cent of patients completed treatment with local recurrence rate of 22.7%. The 5-year and 10-year survival rates were 56.31% (95% CI: 46.20, 65.24) and 22.33% (95% CI: 14.86, 30.76), respectively. The 5-year event-free survival was 52.94% (95% CI: 41.83, 62.87). In multivariate analysis, the independent prognostic factors were presence of metastasis and completion of treatment for both 5-year and 10-year overall survival. Good histological response was only significant for multivariate analysis at 5 years. Patients with metastasis had a hazard ratio of 20.4 at 5 years and 3.26 at 10 years. Conclusion: Overall survival rate for osteosarcoma patients at our centre was comparably higher than other centres in the region. Two independent risk factors for survival are metastatic status and completion of treatment. A standardized chemotherapy regime is essential for long-term survival.

IMPDH2 and HPRT expression and a prognostic significance in preoperative and postoperative patients with osteosarcoma

“…Our previous study reported 37.9% of the 5-year overall survival rates in Northern Thailand 5 . This finding is comparable with studies conducted within Asia–Pacific region reporting 27–48% of the 5-year overall survival rates that were much lower in comparison to western regions with rates between 60 and 70% 6 . Major factors of the poor clinical outcomes were presence of metastasis and not completing treatment regarding patients’ non-compliance to treatment regime.…”

Development and Validation of Nomogram-Based Prognosis Tools for Patients with Extremity Osteosarcoma: A SEER Population Study

“…In the training cohort of 856 samples, 39.3% of patients died at or before their last follow-up, over 90% of whom died from cancer-specific causes. 5-year OS and CSS rates were found to be 64.0% and 65.8%, respectively, which were at the higher end of what was previously reported in research articles discussing the survival prediction of osteosarcoma [ 47 – 49 ].…”

Potential Anti-Metastatic Role of the Novel miR-CT3 in Tumor Angiogenesis and Osteosarcoma Invasion

“…The five-year survival rate for patients diagnosed with non-metastatic OS has increased to 70–80% through wide resection surgery combined with multi-drug adjuvant chemotherapy [ 2 ]. Nevertheless, more than 60% patients developed metastasis during treatment with 39% presenting lung metastasis [ 3 ]. Notably, the 5-year survival rate of patients who develop chemo-resistance decreased to less than 20%, supporting in turn a rapid growth of metastatic lesions [ 4 ].…”